Skip to main content
SpringerLink
Log in

Medical Treatment of Neuroendocrine Tumors

  • Chapter
  • First Online:
Book cover Endocrine Pathology:

  • 2200 Accesses

Abstract

The management of gastrointestinal neuroendocrine tumors takes into consideration the clinical stage of the disease, any symptoms from disease bulk or hormone overproduction, and the clinical pace of the disease. Options for therapy include observation, octreotide to reduce hormonal secretion, or other more toxic therapies such as interferon-α, chemotherapy, or molecularly targeted therapies under investigation. Surgery or embolic therapy to branches of the hepatic artery may also assist in the management of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moertel CG (1987) Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5:1502–1522

    CAS  PubMed  Google Scholar 

  2. Kvols LK, Martin JK, Marsh HM, Moertel CG (1985) Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 313:1229–1230

    CAS  PubMed  Google Scholar 

  3. Connolly HM, Nishimura RA, Smith HC et al (1995) Outcome of cardia surgery for carcinoid heart disease. J Am Coli Cardio 25:410–416

    Article  CAS  Google Scholar 

  4. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600–606

    CAS  PubMed  Google Scholar 

  5. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38:430–438

    Article  CAS  PubMed  Google Scholar 

  6. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94:331–343

    Article  CAS  PubMed  Google Scholar 

  7. Arnold R, Müller H, Schade-Brittinger C, Rinke A, Klose K, Varth P, Wied M, Mayer C, Aminossadati B, PROMID Sturdy Group (2009) Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. Gastrointestinal Cancers Symposium Proceedings 121:120. Abstract

    Google Scholar 

  8. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy and survival. J Clin Oncol 26(13):2124–2130

    Article  CAS  PubMed  Google Scholar 

  9. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169:36–42 discussion 42–43

    Article  CAS  PubMed  Google Scholar 

  10. Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30:969–985

    CAS  PubMed  Google Scholar 

  11. Moertel CG, Johnson CM, McKusick MA, Lopez RR, Wright JK Jr, Chapman WC, Webb L, Mazer M, Meranze S, Pinson CW (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120:302–309

    CAS  PubMed  Google Scholar 

  12. Dominguez S, Denys A, Madeira I, Hammel P, Vilgrain V, Menu Y, Bernades P, Ruszniewski P (2000) Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours (see comments). Eur J Gastroenterol Hepato 12:151–157

    Article  CAS  Google Scholar 

  13. Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK Jr, Chapman WC, Webb L, Mazer M, Meranze S, Pinson CW (1998) Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 175:408–412

    Article  CAS  PubMed  Google Scholar 

  14. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S (1998) Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. Am J Roentgenol 170:339–344

    CAS  Google Scholar 

  15. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M, Mignon M (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71:2624–2630

    Article  CAS  PubMed  Google Scholar 

  16. Kvols LK, Buck M (1987) Chemotherapy of endocrine malignancies: a review. Semin Oncol 14:343–353

    CAS  PubMed  Google Scholar 

  17. Moertel CG, Hanley JA (1979) Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2:327–334

    CAS  PubMed  Google Scholar 

  18. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2:1255–1259

    CAS  PubMed  Google Scholar 

  19. Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B, Costanzi JH (1987) A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60:2891–2895

    Article  CAS  PubMed  Google Scholar 

  20. Rougier P, Oliveira J, Ducreux M, Theodore C, Kac J, Droz JP (1991) Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-f1uorouracil, doxorubicin and cisplatin. Eur J Cancer 27:1380–1382

    Article  CAS  PubMed  Google Scholar 

  21. Saltz L, Lauwers G, Wiseberg J, Kelsen D (1993) A phase II trial of carboplatin in patients with advanced APUD tumors. Cancer 72:619–622

    Article  CAS  PubMed  Google Scholar 

  22. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J (2001) A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91:1543–1548

    Article  CAS  PubMed  Google Scholar 

  23. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194

    Article  CAS  PubMed  Google Scholar 

  24. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523

    Article  CAS  PubMed  Google Scholar 

  25. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232

    Article  CAS  PubMed  Google Scholar 

  26. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101–1107

    Article  CAS  PubMed  Google Scholar 

  27. Oberg K, Eriksson B (1991) The role of interferons in the management of carcinoid tumors. Acta Oncol 30:519–522

    Article  CAS  PubMed  Google Scholar 

  28. Eriksson B, Oberg K (1993) An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32:203–208

    Article  CAS  PubMed  Google Scholar 

  29. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R (1999) Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94:1381–1387

    CAS  PubMed  Google Scholar 

  30. Tiensuu Janson EM, Ahlstrom H, Andersson T, Oberg KE (1992) Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28A:1647–1650

    Article  CAS  PubMed  Google Scholar 

  31. Moertel CG, Rubin J, Kvols LK (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7:865–868

    CAS  PubMed  Google Scholar 

  32. Faiss S, Pape U-F, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21(14):2689–2696

    Article  CAS  PubMed  Google Scholar 

  33. Hobday TJ, Rubin J, Goldberg R, et al. (2003) Molecular markers in metastatic gastrointestinal neuroendocrine tumors. In: Annual Meeting of American Society of Clinical Oncology. American Society of Clinical Oncology, Chicago, IL, p 269

    Google Scholar 

  34. Hobday T, Holen K, Donehower R et al (2006) A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 24:189s

    Google Scholar 

  35. Kulke MH, Lenz H-J, Meropol NJ, Posey J, Ryan DP, Picus J, Em B, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26(20):3403–3410

    Article  CAS  PubMed  Google Scholar 

  36. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C (2007) MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2007 ASCO Annu Meet Proc Part 1 25(18S):199s

    Google Scholar 

  37. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hossen S, St. Peter J, Haas T, Widenmann B (2009) Gastrointestinal Cancers Symposium Proceedings 122:121. Abstract

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA

    Timothy J. Hobday

Authors
  1. Timothy J. Hobday
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy J. Hobday .

Editor information

Editors and Affiliations

  1. Dept. Laboratory Medicine & Pathology, Mayo Clinic, First Street SW 200, Rochester, 55905, U.S.A.

    Ricardo V. Lloyd

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hobday, T.J. (2010). Medical Treatment of Neuroendocrine Tumors. In: Lloyd, R. (eds) Endocrine Pathology:. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1069-1_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1069-1_28

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-1068-4

  • Online ISBN: 978-1-4419-1069-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation